Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine
Sponsor: Mayo Clinic
Summary
This prospective, single-arm feasibility study will evaluate postoperative pain control, opioid use, and early recovery outcomes in adult patients undergoing elective outpatient facial plastic surgery who receive suzetrigine as part of their standard postoperative analgesic regimen.
Official title: Opioid Avoidance In Surgery Through Integrating Suzetrigine: Post-Operative Care Phase Pilot
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-03
Completion Date
2028-03
Last Updated
2025-12-02
Healthy Volunteers
No
Conditions
Interventions
Suzetrigine
Patients will receive suzetrigine instead of the standard of care opioids. The dosing schedule will be: a single oral loading dose of 100 mg suzetrigine, followed by 50 mg every 12 hours starting 12 hours after the first dose. Treatment will begin right after surgery and continue for up to 7 days. All patients will also receive acetaminophen (650 mg every 6 hours) and celecoxib (200 mg every 24 hours) as part of the standard multimodal pain management regimen. Patients experiencing breakthrough pain will be prescribed rescue opioid medication (oxycodone 5 mg every 6 hours as needed) and use will be recorded.
Locations (1)
Mayo Clinic in Florida
Jacksonville, Florida, United States